In a report released today, Hartaj Singh from Oppenheimer maintained a Hold rating on aTyr Pharma (LIFE – Research Report). The company’s shares closed yesterday at $1.14.
Singh covers the Healthcare sector, focusing on stocks such as Moderna, Eloxx Pharmaceuticals, and Viracta Therapeutics. According to TipRanks, Singh has an average return of 10.5% and a 44.13% success rate on recommended stocks.
aTyr Pharma has an analyst consensus of Strong Buy, with a price target consensus of $21.50.
See the top stocks recommended by analysts >>
The company has a one-year high of $2.70 and a one-year low of $1.08. Currently, aTyr Pharma has an average volume of 167K.
Based on the recent corporate insider activity of 14 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of LIFE in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
aTyr Pharma (LIFE) Company Description:
aTyr Pharma, Inc. develops protein therapeutics and novel class of biologic drugs. It plans to build a pipeline of therapeutic products based on Physiocrine biology. The company has established a dominant intellectual property estate to protect the core therapeutics as well as associated diagnostics. aTyr Pharma was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.
Read More on LIFE:
- aTyr Pharma’s efzofitimod shows immune function in rheumatoid arthritis
- aTyr Pharma Presents Poster Demonstrating Preclinical Effects of Efzofitimod in Rheumatoid Arthritis and Rheumatoid Arthritis-Associated ILD at the ACR Convergence 2023
- aTyr Pharma files $300M mixed securities shelf
- aTyr Pharma reports Q3 EPS (20c), consensus (23c)
- aTyr Pharma to Present at November Investor Conferences
